Doxycycline

證據等級: L5

預測適應症: 10 個

Doxycycline: From Bacterial Infections to Punctate Epithelial Keratoconjunctivitis

One-Sentence Summary

Doxycycline is a broad-spectrum tetracycline antibiotic serving as first-line treatment for intracellular bacterial infections including Chlamydia trachomatis, Rickettsia species, and Borrelia burgdorferi. The TxGNN model predicts it may be effective for Punctate Epithelial Keratoconjunctivitis, with 0 clinical trials and 1 publication currently supporting this direction.

Quick Overview

Item	Content
Original Indication	Broad-spectrum bacterial infections (chlamydia, rickettsia, Lyme disease, etc.) — no Philippines registration on file
Predicted New Indication	Punctate Epithelial Keratoconjunctivitis
TxGNN Prediction Score	99.94%
Evidence Level	L4
Philippines Market Status	Not marketed
Number of Registrations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available from this Evidence Pack. Based on known information, Doxycycline is a tetracycline-class antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit and blocking aminoacyl-tRNA attachment. This mechanism gives it particular potency against obligate intracellular organisms — notably Chlamydia trachomatis, Rickettsia spp., and Borrelia burgdorferi — that evade many conventional antibiotics.

The mechanistic link to punctate epithelial keratoconjunctivitis centers on Chlamydia trachomatis as the shared pathogen. Chlamydial follicular conjunctivitis is a recognized antecedent of punctate epithelial keratitis: the organism invades conjunctival and corneal epithelial cells, triggering an inflammatory cascade that produces characteristic grayish punctate corneal lesions, sometimes with anterior stromal edema. As the WHO-recommended first-line treatment for chlamydial infections, Doxycycline’s ability to eliminate the underlying pathogen makes this connection scientifically plausible.

A secondary mechanism may also be relevant: Doxycycline inhibits matrix metalloproteinases (particularly MMP-9), enzymes implicated in corneal stromal degradation during inflammatory keratitis. This host-directed anti-inflammatory property could theoretically limit corneal tissue damage beyond bacterial clearance alone. That said, this prediction largely reflects Doxycycline’s established role in chlamydial disease rather than a novel repurposing. Systematic clinical validation specifically targeting punctate epithelial keratoconjunctivitis as a primary endpoint is absent.

Clinical Trial Evidence

Currently no related clinical trials registered for this indication.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
1424659	1992	Case Series / Retrospective	Cornea	Two patients with C. trachomatis follicular conjunctivitis treated with oral tetracycline or doxycycline resolved their follicles, but subsequently developed persistent, recurrent bilateral grayish punctate corneal lesions with fluorescein staining and anterior stromal edema — suggesting post-infectious corneal sequelae may persist or recur despite successful antibiotic clearance of the original infection

Philippines Market Information

Doxycycline is currently not registered with the Philippine FDA (FDA-PH). No product authorization records are on file. This may reflect a regulatory gap rather than safety concerns, as doxycycline is included on the WHO Essential Medicines List and is widely approved in other jurisdictions.

Safety Considerations

Please refer to the package insert for safety information.

Note: Philippines FDA package insert data (warnings and contraindications) were identified as a blocking data gap (DG001) for this evaluation. Drug interaction data was also unavailable (query returned no results). These gaps must be resolved before any clinical decision-making.

Conclusion and Next Steps

Decision: Hold

Rationale: The sole supporting evidence is a single 1992 retrospective case series (n=2, L4), and the identified mechanistic link reflects Doxycycline’s already-established efficacy against chlamydial infections rather than a genuine novel repurposing opportunity. No registered clinical trials address punctate epithelial keratoconjunctivitis as a primary endpoint, and both key safety data items (TFDA/FDA-PH package insert warnings and MOA characterization) remain unresolved blocking gaps.

To proceed, the following is needed:

Safety data (Blocking): Obtain Philippine FDA package insert PDF and parse warnings, contraindications, and precautions before any safety assessment can proceed
MOA data (High priority): Query DrugBank API for DB00254 to formally characterize mechanism and strengthen or challenge the repurposing rationale
Clinical evidence: Identify or design a prospective clinical study specifically evaluating Doxycycline in punctate epithelial keratoconjunctivitis (chlamydial etiology confirmed by PCR/culture)
Patient population definition: Distinguish chlamydial vs. non-chlamydial (viral, allergic, toxic) etiologies of punctate keratoconjunctivitis, as Doxycycline would only be expected to benefit the infectious subtype
Philippines registration pathway: If clinical evidence is ultimately sufficient, evaluate a supplemental indication filing with FDA-PH given zero current market presence

⚠️ Disclaimer: This report is for research reference only and does not constitute medical advice. Drug repurposing candidates require clinical validation before any therapeutic application.

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.